Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Neoadjuvant Chemoradiation in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT02812641Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2016
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by National Taiwan University Hospital. Primary endpoints: Dose-limiting toxicity and Pathological complete response rate at 8 weeks. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02812641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812641.